Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06576167 · ClinicalTrials.gov registry record · NA
COVID-19 Self-testing IMPROVE
A NA study of COVID-19, sponsored by Temple University.
- Completed
- Registry status
- NA
- Development phase
- 1,271
- Enrollment target
- 1
- Study location
NCT06576167: Completed NA study of COVID-19, sponsored by Temple University.
NCT06576167 is a NA study of COVID-19 that has completed, run by Temple University. The registered enrollment target is 1,271 participants, below the 38,461-participant average among 298 other COVID-19 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06576167, a NA study of COVID-19, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,271 participants
- Enrollment target
- 1
- Study location
Study Summary
The study aims to engage community partners to implement IMPROVE intervention and promote (COVID-19) rapid testing among vulnerable Asian Americans in the Greater Philadelphia Area and New York City
Primary Outcome
Lifetime use defined as self-report of ever using a COVID-19 rapid antigen home self-test kit at least once. Baseline was collected before IMPROVE implementation for all participants. The 1-month and 3-month follow-up assessments were collected after participants received the IMPROVE intervention, according to their wedge rollout schedule. Cleaned dataset with corrected data collection dates was used to update the results.
Conditions Studied
Interventions
- BEHAVIORAL IMPROVE
Study Locations (1)
Pennsylvania
- Center for Asian Health, Lewis Katz School of Medicine, Temple University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,271 participants |
| Start Date | 2023-06-15 |
| Est. Completion | 2024-12-02 |
| Phase | NA |
What the finished NCT06576167 record still lists
NCT06576167 is an interventional study that assigns participants to a tested intervention. Its 1,271 participants enrollment target places it among the larger protocols in the corpus, below the 38,461-participant average among 298 other COVID-19 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which IMPROVE is the first listed.
NCT06576167 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06576167 about?
NCT06576167 is a clinical study titled "COVID-19 Self-testing IMPROVE". The study aims to engage community partners to implement IMPROVE intervention and promote (COVID-19) rapid testing among vulnerable Asian Americans in the Greater Philadelphia Area and New York City
What is the current status of trial NCT06576167?
This trial is currently completed. It is a NA study. The enrollment target is 1,271 participants. The study started on 2023-06-15. Estimated completion is 2024-12-02.
What conditions does trial NCT06576167 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT06576167?
The interventions under investigation include: IMPROVE (BEHAVIORAL).
Who is sponsoring clinical trial NCT06576167?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06576167 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06576167's enrollment target sits among peer trials
1,271 60th of 298 higher than 239 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Music Mindfulness Study 2a.
RECRUITING · NA
-
Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)
RECRUITING · NA
-
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
RECRUITING · NA
-
Evaluating the Impact of Social Music
RECRUITING · NA
-
The SINCERE Intervention to Address COVID-19 Health Disparities
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06790641 · 1,270 participants · NA
Pathways to Perinatal Mental Health Equity
- NCT06876246 · 1,270 participants · NA
SBIR/ STTR Family Check-up Online
- NCT03678025 · 1,273 participants · Phase 3
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- NCT07225504 · 1,275 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI